Windtree Therapeutics Inc (WINT) Stock Price, Quote & News

Company Profile

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company is also developing AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature...

Industry: Biotechnology

Sector: Healthcare

Phone: 215 488 9300

Website: windtreetx.com

Address:

2600 Kelly Road, Suite 100, Warrington, United States

BenedictArthurKnight Jul. 26 at 8:41 PM

$WINT data due in July and we only have a week left. Looks ready to get sent. Most dilution should be done from all the recent volume

0 · Reply

JohnDoesit Jul. 26 at 8:49 AM

$WINT didn’t you get out at 0,97? Everyone’s aware of the high risk holding shares in this company but some choses to hold despite that fact. If you chose to sell u should move on to the next one instead of staying on here bashing the stock with guesses.. gl to u brother

0 · Reply

HighFlyingProfits Jul. 26 at 1:24 AM

$MCVT Wow, he nailed it.. Drop this @_ICEMAN a FOLLOW below I made 13.5k$ profit on his MCVT pick, my biggest win in trading so far. Huge squeezer.. Im also holding: $SYTA $NCNA $GIBO $WINT in to next week - Lets bank bulls

0 · Reply

PlayedOutNCruel Jul. 25 at 10:53 PM

$WINT It is already Friday afternoon, the only relevant event is in Margaritaville !!!

0 · Reply

artist123 Jul. 25 at 7:54 PM

$WINT HUNDREDS OF MILLIONS OF DOLLARS HAVE BEEN LOST IN THIS SHELL GAME. DON'T FALL FOR IT!!!

1 · Reply

RB818 Jul. 25 at 7:37 PM

$WINT Get ready for your Friday afternoon filings. They may wait until 6pm or even 7, when fewer people are around to notice.

1 · Reply

artist123 Jul. 25 at 7:29 PM

A dollar invested in $WINT is like a dollar invested in $TRIQ and $RENO and $TESI. BioHiTech become Renovare ($RENO), then become Traqiq ($TRIQ), then become Titan Environmental ($TESI), and then become Windtree ($WINT in the span of 4 years. Investors in those older shell companies have been BANKRUPTED. Know the FACTS! This is a SCAM!!!

1 · Reply

cvv44 Jul. 25 at 7:29 PM

$WINT added a few more why not

0 · Reply

fromtheothersid3 Jul. 25 at 7:27 PM

$WINT Bring the eod push out of this flag ☺️

1 · Reply

fromtheothersid3 Jul. 25 at 7:09 PM

$WINT imho next week will ne sweet indeed... Strong Close today above 1,05$ and more would be fun ☺️

0 · Reply

Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy

Jul 16, 2025, 9:22 AM EDT - 10 days ago

Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions

Jul 2, 2025, 9:00 AM EDT - 24 days ago

Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure

Jun 26, 2025, 4:05 PM EDT - 4 weeks ago

Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel

May 22, 2025, 8:16 AM EDT - 2 months ago

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

May 12, 2025, 8:00 AM EDT - 2 months ago

Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025

May 6, 2025, 8:18 AM EDT - 2 months ago

Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

Mar 26, 2025, 8:47 AM EDT - 4 months ago

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

Mar 24, 2025, 8:30 AM EDT - 4 months ago

Evofem Reports Fourth Consecutive Year of Net Sales Growth

ADTX

Mar 24, 2025, 8:00 AM EDT - 4 months ago

Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules

Mar 20, 2025, 8:00 AM EDT - 4 months ago

Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product

Jan 15, 2025, 8:00 AM EST - 6 months ago

Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline

Jan 13, 2025, 8:00 AM EST - 6 months ago

Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

Dec 9, 2024, 8:00 AM EST - 8 months ago

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

Dec 4, 2024, 8:00 AM EST - 8 months ago

Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

Nov 27, 2024, 4:05 PM EST - 8 months ago

Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

Oct 23, 2024, 8:00 AM EDT - 9 months ago

Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World

Oct 17, 2024, 8:15 AM EDT - 10 months ago

Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan

Sep 30, 2024, 8:15 AM EDT - 10 months ago

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Sep 26, 2024, 4:05 PM EDT - 10 months ago

Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET

Sep 25, 2024, 8:15 AM EDT - 10 months ago

Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Aug 20, 2024, 4:05 PM EDT - 1 year ago

Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Windtree Announces New Additions and Changes to Its Board of Directors

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data

May 7, 2024, 8:00 AM EDT - 1 year ago

Windtree Therapeutics Regains Compliance with Nasdaq

Apr 22, 2024, 11:06 AM EDT - 1 year ago

What made Windtree Therapeutics stock tank 20% on Monday?

Apr 18, 2024, 8:00 AM EDT - 1 year ago

Windtree Therapeutics Announces Reverse Stock Split

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates

Apr 8, 2024, 4:48 PM EDT - 1 year ago

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

Feb 1, 2024, 8:00 AM EST - 1 year ago

Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

Jan 31, 2024, 8:00 AM EST - 1 year ago

Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives

Jan 26, 2024, 9:20 AM EST - 1 year ago

Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company

Jan 25, 2024, 8:30 AM EST - 1 year ago

Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company

Jan 18, 2024, 9:00 AM EST - 1 year ago

Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China

Jan 17, 2024, 8:00 AM EST - 1 year ago

Windtree Therapeutics Announces License Agreement with Lee's Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region

Jan 2, 2024, 4:05 PM EST - 1 year ago

Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator

Dec 19, 2023, 9:30 AM EST - 1 year ago

Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024

Dec 18, 2023, 8:00 AM EST - 1 year ago

Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Nov 16, 2023, 8:00 AM EST - 1 year ago

Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent

Nov 9, 2023, 4:15 PM EST - 1 year ago

Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates

Nov 8, 2023, 8:00 AM EST - 1 year ago

Windtree to Present at the Sidoti Micro Cap Conference on November 16th

Oct 12, 2023, 7:30 AM EDT - 1 year ago

Windtree to Present at the ThinkEquity Conference on October 19th in New York City

Oct 10, 2023, 7:30 AM EDT - 1 year ago

Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th

Oct 3, 2023, 8:00 AM EDT - 1 year ago

Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th

Aug 23, 2023, 8:00 AM EDT - 2 years ago

Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office

Aug 16, 2023, 9:00 AM EDT - 2 years ago

Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market

Aug 7, 2023, 4:05 PM EDT - 2 years ago

Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates

Jul 25, 2023, 9:25 AM EDT - 2 years ago

Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure

Jul 18, 2023, 9:00 AM EDT - 2 years ago

The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market

Jul 14, 2023, 9:00 AM EDT - 2 years ago

Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ:WINT) Is Helping Change That

BenedictArthurKnight Jul. 26 at 8:41 PM

$WINT data due in July and we only have a week left. Looks ready to get sent. Most dilution should be done from all the recent volume

0 · Reply

JohnDoesit Jul. 26 at 8:49 AM

0 · Reply

HighFlyingProfits Jul. 26 at 1:24 AM

0 · Reply

PlayedOutNCruel Jul. 25 at 10:53 PM

$WINT It is already Friday afternoon, the only relevant event is in Margaritaville !!!

0 · Reply

artist123 Jul. 25 at 7:54 PM

$WINT HUNDREDS OF MILLIONS OF DOLLARS HAVE BEEN LOST IN THIS SHELL GAME. DON'T FALL FOR IT!!!

1 · Reply

RB818 Jul. 25 at 7:37 PM

$WINT Get ready for your Friday afternoon filings. They may wait until 6pm or even 7, when fewer people are around to notice.

1 · Reply

artist123 Jul. 25 at 7:29 PM

1 · Reply

cvv44 Jul. 25 at 7:29 PM

$WINT added a few more why not

0 · Reply

fromtheothersid3 Jul. 25 at 7:27 PM

$WINT Bring the eod push out of this flag ☺️

1 · Reply

fromtheothersid3 Jul. 25 at 7:09 PM

$WINT imho next week will ne sweet indeed... Strong Close today above 1,05$ and more would be fun ☺️

0 · Reply

ferrisss Jul. 25 at 6:50 PM

$WINT yesterday's news effect and promised trial data yet to come.

0 · Reply

fromtheothersid3 Jul. 25 at 6:33 PM

$WINT Bring the eod friday Leg ☺️

0 · Reply

bullish51892 Jul. 25 at 5:51 PM

$WINT If this crosses $1.0 and holds I’m loading up for Monday 🤑🤑

0 · Reply

AzizAzizJ1 Jul. 25 at 5:50 PM

$WINT It must be at least over $1

0 · Reply

madw77 Jul. 25 at 5:36 PM

$WINT red to green. It is very undervalued here. Yesterday's news was huge!

0 · Reply

fromtheothersid3 Jul. 25 at 5:33 PM

$WINT lets get the.move Would be great to Close above 1,05 and Higher ☺️

0 · Reply

Power__It_up Jul. 25 at 5:32 PM

$WINT Join us at GIBO

0 · Reply

fromtheothersid3 Jul. 25 at 5:12 PM

$WINT coming Back ☺️

0 · Reply

Alogan1 Jul. 25 at 5:02 PM

$WINT i hope that 55k bid at 96 is a good guy - we will see shortly

0 · Reply

Kazeek06 Jul. 25 at 4:55 PM

$WINT Watching.

0 · Reply

fromtheothersid3 Jul. 25 at 4:45 PM

$WINT come in, Bring the squeezeee ☺️

0 · Reply

Alogan1 Jul. 25 at 4:40 PM

$WINT looks like we're at that 95 for another shake out prior to closing. I think will close out 1.09 with out some more strong buyers hitting ask - don't listen to me though I'm noob

0 · Reply

Market Cap	3.59M
Revenue (ttm)	0.00
Net Income (ttm)	-1.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.05

Volume	3,794,400
Avg Vol	13,091,822
Day's Range	N/A - N/A
Shares Out	3.66M
Stochastic %K	27%
Beta	0.70
Analysts	Strong Buy
Price Target	$4.00